AACR to Host Two Press Teleconferences at Pancreatic Cancer Conference
NEW ORLEANS — The American Association for Cancer Research (AACR) will host two press teleconferences at its special conference on Pancreatic Cancer: Innovations in Research and Treatment, May 18-21 at the Hyatt Regency New Orleans.
A press kit containing embargoed news releases and highlighted abstracts will be available to media May 13.
The first teleconference will be held Monday, May 19, 10 a.m. CT. Reporters can dial in at 866-297-6395 (United States/Canada) or 847-944-7317 (international), and should offer confirmation code 37195596 when prompted. It will include:
- Analyses projecting paradigm-shifting pancreatic cancer mortality rates;
- Updated results of a phase Ib trial combining gemcitabine with a new radioimmunotherapy for metastatic pancreatic cancer;
- Development and validation of a blood-based biomarker panel for detection of early-stage pancreatic cancer; and
- Preclinical results indicating CD47 may be a therapeutic target for pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma.
On Wednesday, May 21, 10 a.m. CT, conference leaders David Tuveson, M.D., Ph.D., The Lustgarten Foundation and Cold Spring Harbor Laboratories; Christine Iacobuzio-Donahue, M.D., Memorial Sloan Kettering Cancer Center; and Alec Kimmelman, M.D., Ph.D., Dana-Farber Cancer Institute, will offer analysis of the conference, including discussion of exciting new research areas and potential treatment options.
Reporters who join that press teleconference should dial 866-297-6395 (United States/Canada) or 847-944-7317 (international) and offer confirmation code 37264783 when prompted.
Read the conference program.